Managed care
Southern California Permanente Medical Group
Southern California Permanente Medical Group was paid $48.19M by Medicaid between Jan 2018 and Dec 2024, across 396 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 18% of everything it billed.
33Billing provider infoSOUTHERN CALIFORNIA PERMANENTE MEDICAL GROUP
LOS ANGELES, CA 90027
LOS ANGELES, CA 90027
33aNPI1134151657assigned 07/07/2006
33bProvider typeHealth Maintenance Organization
28Total paid$48.19M
24GClaims1,100,248
24DCodes billed396
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Health Maintenance Organization providers in California
Rank by total paid#2 of 151
Median peer was paid$59K
This provider vs. median816×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DAVIDOFF, RAMIN controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 103,776 | $255K | |
| 2019 | 139,570 | $1.14M | |
| 2020 | 105,998 | $3.49M | |
| 2021 | 146,658 | $6.27M | |
| 2022 | 156,036 | $7.71M | |
| 2023 | 196,018 | $11.68M | |
| 2024incomplete | 252,192 | $17.64M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 18% | 93,944 | 91,332 | $8.76M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.1% | 45,943 | 44,956 | $4.40M |
| 77386 | 6.4% | 5,646 | 3,445 | $3.10M | |
| 91320 | 4.3% | 12,196 | 12,188 | $2.06M | |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 4.0% | 76,626 | 74,451 | $1.92M |
| 78815 | Positron emission tomography (PET) for limited area imaging | 3.6% | 1,051 | 1,044 | $1.74M |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 3.1% | 21,264 | 15,656 | $1.50M |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | 2.4% | 798 | 783 | $1.14M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 2.0% | 21,843 | 21,290 | $980K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.8% | 7,045 | 5,487 | $857K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.7% | 4,927 | 4,492 | $842K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 1.7% | 88,650 | 88,223 | $805K |
384 more codes
| 90480 | 1.6% | 14,762 | $780K | |
| 70450 | Computed tomography, head or brain; without contrast material | 1.5% | 14,334 | $729K |
| 90662 | 1.3% | 5,842 | $648K | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | 1.3% | 10,443 | $648K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.2% | 27,219 | $598K |
| 67028 | Intravitreal injection of a pharmacologic agent | 1.2% | 2,735 | $594K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.2% | 19,313 | $560K |
| J0178 | Injection, aflibercept, 1 mg | 1.1% | 181 | $527K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | 1.0% | 5,481 | $497K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 638 | $475K |
| 99285 | Emergency room visit (most serious) | <1% | 4,673 | $453K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,743 | $442K |
| 90961 | <1% | 586 | $400K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,557 | $384K |
| 77080 | <1% | 11,876 | $379K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 10,640 | $373K |
| 90962 | <1% | 695 | $372K | |
| 92015 | Determination of refractive state | <1% | 27,949 | $309K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 23,623 | $292K |
| 99442 | <1% | 4,652 | $290K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,377 | $254K |
| 90686 | <1% | 40,631 | $253K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,998 | $253K |
| 92134 | <1% | 8,366 | $236K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,229 | $233K |
| 11721 | <1% | 2,714 | $230K | |
| 99441 | <1% | 8,604 | $216K | |
| 73562 | <1% | 8,364 | $187K | |
| 71045 | Radiologic examination, chest; single view | <1% | 46,000 | $186K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,557 | $178K |
| 0064A | <1% | 4,308 | $176K | |
| 78451 | <1% | 444 | $171K | |
| 0002A | <1% | 4,438 | $170K | |
| 92557 | <1% | 3,237 | $169K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 4,313 | $167K |
| 73564 | <1% | 4,808 | $162K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 6,911 | $161K |
| 0001A | <1% | 4,350 | $159K | |
| 0012A | <1% | 4,236 | $154K | |
| 73030 | <1% | 7,289 | $154K | |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 1,695 | $147K |
| 97161 | <1% | 1,393 | $141K | |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 2,351 | $141K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 1,293 | $140K |
| 76830 | Ultrasound, transvaginal | <1% | 4,325 | $139K |
| 76770 | <1% | 2,260 | $135K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 14,938 | $132K |
| 71250 | <1% | 757 | $132K | |
| 73630 | <1% | 8,937 | $132K | |
| 0011A | <1% | 3,619 | $131K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 3,057 | $129K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 4,627 | $128K |
| 0124A | <1% | 3,726 | $123K | |
| 76641 | <1% | 2,566 | $120K | |
| G6002 | Stereoscopic x-ray guidance for localization of target volume for the delivery of radiation therapy | <1% | 686 | $120K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 412 | $115K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,152 | $112K |
| 0134A | <1% | 2,990 | $107K | |
| 76536 | <1% | 1,474 | $103K | |
| 88341 | <1% | 525 | $101K | |
| 72100 | <1% | 4,420 | $101K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 5,664 | $99K |
| 92567 | <1% | 4,770 | $91K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 3,493 | $91K |
| 90750 | <1% | 1,029 | $90K | |
| 90837 | Psychotherapy session, about an hour | <1% | 2,310 | $89K |
| 90966 | <1% | 122 | $85K | |
| 92002 | <1% | 2,416 | $82K | |
| 73502 | <1% | 1,947 | $73K | |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | <1% | 316 | $70K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 1,422 | $69K |
| 0054A | <1% | 1,629 | $69K | |
| 0004A | <1% | 1,703 | $68K | |
| J7999 | Compounded drug, not otherwise classified | <1% | 1,039 | $61K |
| 94729 | <1% | 518 | $60K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 3,700 | $59K |
| 73610 | <1% | 4,752 | $58K | |
| 73130 | <1% | 3,398 | $58K | |
| 99443 | <1% | 572 | $57K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 805 | $55K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 370 | $52K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,606 | $50K |
| 77065 | Tomosynthesis, mammo | <1% | 417 | $49K |
| 73110 | <1% | 2,606 | $48K | |
| 92082 | <1% | 1,544 | $48K | |
| 72141 | <1% | 320 | $47K | |
| 94726 | <1% | 388 | $45K | |
| 94060 | <1% | 527 | $44K | |
| 92551 | <1% | 16,735 | $42K | |
| 99397 | <1% | 137 | $41K | |
| 88188 | <1% | 659 | $39K | |
| 92133 | <1% | 1,858 | $38K | |
| 70486 | <1% | 298 | $38K | |
| 0071A | <1% | 890 | $36K | |
| 88189 | <1% | 440 | $34K | |
| 93922 | <1% | 317 | $34K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 1,479 | $33K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 3,492 | $33K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 1,210 | $33K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 10,952 | $32K |
| 90674 | <1% | 1,946 | $32K | |
| 88342 | <1% | 656 | $31K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 8,709 | $29K |
| 94010 | <1% | 571 | $29K | |
| 90678 | <1% | 160 | $29K | |
| 95800 | <1% | 148 | $28K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 360 | $28K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,329 | $27K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 4,321 | $27K |
| 0072A | <1% | 650 | $26K | |
| 20610 | <1% | 186 | $26K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 552 | $25K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 1,826 | $25K |
| 93971 | <1% | 166 | $24K | |
| 80051 | <1% | 4,779 | $24K | |
| 82565 | <1% | 5,486 | $24K | |
| 74018 | <1% | 4,141 | $23K | |
| 74183 | <1% | 68 | $23K | |
| 72050 | <1% | 549 | $22K | |
| 73140 | <1% | 1,732 | $22K | |
| 77066 | Tomosynthesis, mammo | <1% | 159 | $21K |
| 93294 | <1% | 268 | $21K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 1,050 | $21K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,915 | $20K |
| 93271 | <1% | 73 | $20K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 12 | $19K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 8,436 | $19K |
| 93880 | <1% | 123 | $19K | |
| 90656 | <1% | 3,474 | $19K | |
| 72040 | <1% | 572 | $18K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,021 | $18K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 38 | $18K |
| 93296 | <1% | 263 | $18K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 634 | $17K |
| 97162 | <1% | 152 | $16K | |
| 85060 | <1% | 549 | $15K | |
| 84460 | <1% | 3,436 | $15K | |
| 83921 | <1% | 1,136 | $14K | |
| 91319 | <1% | 384 | $13K | |
| 69210 | <1% | 289 | $13K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 971 | $13K |
| 84075 | <1% | 2,528 | $13K | |
| 76706 | <1% | 92 | $13K | |
| G6013 | Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 mev | <1% | 23 | $12K |
| 85610 | <1% | 2,984 | $12K | |
| 86360 | <1% | 203 | $12K | |
| 71101 | <1% | 350 | $12K | |
| 82247 | <1% | 2,639 | $12K | |
| 93970 | <1% | 125 | $12K | |
| 73560 | <1% | 345 | $12K | |
| 0031A | <1% | 301 | $12K | |
| 81329 | <1% | 378 | $11K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 93 | $11K |
| 88346 | <1% | 61 | $11K | |
| 70496 | <1% | 81 | $11K | |
| 84484 | <1% | 866 | $11K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 12 | $11K |
| 72197 | <1% | 65 | $11K | |
| 73221 | <1% | 43 | $11K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 449 | $11K |
| 0154A | <1% | 281 | $10K | |
| 90677 | <1% | 127 | $10K | |
| 86359 | <1% | 203 | $10K | |
| 93268 | <1% | 29 | $10K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 123 | $10K |
| 87799 | <1% | 240 | $10K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 284 | $10K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 278 | $9K |
| 77336 | <1% | 353 | $9K | |
| 92504 | <1% | 623 | $9K | |
| 72170 | <1% | 520 | $9K | |
| 76000 | <1% | 1,222 | $9K | |
| 73522 | <1% | 136 | $9K | |
| 90651 | <1% | 494 | $9K | |
| 71271 | <1% | 26 | $8K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 644 | $8K |
| 74178 | <1% | 12 | $8K | |
| 82947 | <1% | 2,691 | $8K | |
| 76870 | <1% | 117 | $8K | |
| 84520 | <1% | 2,775 | $8K | |
| 90670 | <1% | 779 | $8K | |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 10,942 | $8K |
| 73080 | <1% | 573 | $8K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 183 | $8K |
| 77073 | <1% | 145 | $8K | |
| 73590 | <1% | 391 | $7K | |
| 73660 | <1% | 424 | $7K | |
| 77427 | <1% | 30 | $7K | |
| 77387 | <1% | 91 | $7K | |
| 0013A | <1% | 172 | $7K | |
| 51798 | <1% | 288 | $7K | |
| 91200 | <1% | 276 | $7K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 546 | $6K |
| 64642 | <1% | 31 | $6K | |
| 62323 | <1% | 40 | $6K | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 42 | $6K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 199 | $6K |
| 99221 | <1% | 296 | $6K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 632 | $6K |
| 57160 | <1% | 28 | $6K | |
| 64612 | <1% | 28 | $6K | |
| 85097 | <1% | 78 | $6K | |
| 83690 | <1% | 1,314 | $6K | |
| 93458 | <1% | 13 | $6K | |
| 90694 | <1% | 52 | $6K | |
| 90734 | <1% | 306 | $5K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 347 | $5K |
| 31231 | <1% | 38 | $5K | |
| 64643 | <1% | 27 | $5K | |
| 91318 | <1% | 338 | $5K | |
| 99173 | <1% | 10,090 | $4K | |
| 11055 | <1% | 24 | $4K | |
| 94618 | <1% | 64 | $4K | |
| 72070 | <1% | 127 | $4K | |
| 0112A | <1% | 103 | $4K | |
| 51741 | <1% | 133 | $4K | |
| 77412 | <1% | 135 | $4K | |
| 85027 | <1% | 1,026 | $4K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 446 | $4K |
| 81002 | <1% | 1,968 | $4K | |
| 0074A | <1% | 103 | $4K | |
| J1750 | Injection, iron dextran, 50 mg | <1% | 13 | $4K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 111 | $4K |
| 0111A | <1% | 89 | $3K | |
| 73100 | <1% | 117 | $3K | |
| 81003 | <1% | 2,391 | $3K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,221 | $3K |
| 93320 | <1% | 160 | $3K | |
| 97165 | <1% | 91 | $3K | |
| 73552 | <1% | 73 | $3K | |
| 76380 | <1% | 12 | $3K | |
| 93272 | <1% | 72 | $3K | |
| 81513 | <1% | 83 | $3K | |
| 88312 | <1% | 128 | $3K | |
| 98968 | <1% | 169 | $3K | |
| 88313 | <1% | 131 | $3K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 54 | $3K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 120 | $2K |
| 76801 | <1% | 90 | $2K | |
| 70491 | <1% | 14 | $2K | |
| 96415 | <1% | 27 | $2K | |
| 31500 | <1% | 54 | $2K | |
| 36592 | <1% | 68 | $2K | |
| 99177 | <1% | 2,196 | $2K | |
| 95117 | <1% | 528 | $2K | |
| 97597 | <1% | 15 | $2K | |
| 0003A | <1% | 53 | $2K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 383 | $2K |
| 70498 | <1% | 38 | $2K | |
| 76881 | <1% | 111 | $2K | |
| 93325 | <1% | 171 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 310 | $2K |
| 90648 | <1% | 841 | $2K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 278 | $2K |
| 76813 | <1% | 36 | $2K | |
| 92523 | <1% | 39 | $2K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 280 | $1K |
| 88307 | <1% | 18 | $1K | |
| 99223 | Prolong inpt eval add15 m | <1% | 141 | $1K |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | <1% | 551 | $1K |
| 0081A | <1% | 33 | $1K | |
| 87338 | <1% | 626 | $1K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 105 | $1K |
| 73060 | <1% | 45 | $1K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 28 | $1K |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 162 | $1K |
| 0082A | <1% | 29 | $1K | |
| 73090 | <1% | 181 | $1K | |
| 99417 | Prolong home eval add 15m | <1% | 67 | $1K |
| 97163 | <1% | 13 | $1K | |
| 73120 | <1% | 43 | $1K | |
| 99472 | Subsequent inpatient pediatric critical care, per day, 2-5 years | <1% | 27 | $992.45 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 776 | $936.56 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 30 | $903.00 |
| 72082 | <1% | 15 | $890.43 | |
| 90746 | <1% | 29 | $872.97 | |
| 96112 | <1% | 75 | $862.00 | |
| 0052A | <1% | 21 | $851.34 | |
| 87081 | <1% | 254 | $822.43 | |
| 99100 | <1% | 15 | $819.00 | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 29 | $728.00 |
| 72081 | <1% | 63 | $716.94 | |
| 36556 | <1% | 15 | $706.32 | |
| 87210 | <1% | 1,130 | $694.96 | |
| 93304 | <1% | 20 | $663.40 | |
| 88304 | <1% | 91 | $652.20 | |
| 99354 | <1% | 105 | $598.91 | |
| 88348 | <1% | 25 | $575.00 | |
| 99051 | <1% | 34,543 | $567.66 | |
| 82105 | <1% | 1,821 | $566.80 | |
| 0053A | <1% | 15 | $560.00 | |
| 0051A | <1% | 13 | $520.00 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 17 | $516.41 |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 14 | $505.00 |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 15 | $432.00 |
| 73565 | <1% | 12 | $420.00 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 20 | $351.53 |
| 0083A | <1% | 67 | $338.50 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 14 | $322.00 |
| 93308 | <1% | 16 | $295.87 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 21 | $256.00 |
| 90633 | <1% | 155 | $226.00 | |
| 73000 | <1% | 13 | $223.27 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 121 | $199.12 |
| 99201 | <1% | 108 | $197.85 | |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | <1% | 13 | $194.97 |
| 84439 | <1% | 64 | $182.89 | |
| 88108 | <1% | 12 | $180.00 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 221 | $171.86 |
| 36415 | Collection of venous blood by venipuncture | <1% | 187 | $150.40 |
| 90655 | <1% | 42 | $140.00 | |
| 82607 | <1% | 37 | $135.59 | |
| 88264 | <1% | 13 | $134.34 | |
| 99205 | Prolong outpt/office vis | <1% | 25 | $115.88 |
| 90660 | <1% | 25 | $114.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 110 | $108.77 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 223 | $102.32 |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 66 | $94.00 |
| 86580 | <1% | 30 | $90.00 | |
| 84450 | <1% | 24 | $85.26 | |
| 82985 | <1% | 13 | $83.16 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 162 | $79.88 |
| 82043 | <1% | 232 | $79.58 | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 12 | $75.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 62 | $62.89 |
| 90715 | <1% | 12 | $61.00 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 23 | $54.50 |
| 90723 | <1% | 114 | $45.00 | |
| 85730 | <1% | 13 | $45.00 | |
| 84702 | <1% | 2,820 | $40.00 | |
| 99188 | <1% | 13 | $32.00 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 114 | $29.42 |
| 99462 | <1% | 43 | $27.22 | |
| 82677 | <1% | 1,720 | $26.07 | |
| 86336 | <1% | 1,724 | $16.80 | |
| 84403 | <1% | 14 | $10.08 | |
| 84590 | <1% | 14 | $8.40 | |
| 92227 | <1% | 91 | $7.91 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 17 | $4.47 |
| G9920 | Screening performed and negative | <1% | 3,221 | $0.06 |
| 81241 | 0% | 147 | $0.00 | |
| 90661 | 0% | 668 | $0.00 | |
| 81207 | 0% | 136 | $0.00 | |
| 80061 | Lipid panel | 0% | 242 | $0.00 |
| 82274 | 0% | 123 | $0.00 | |
| 81025 | 0% | 16 | $0.00 | |
| 81206 | 0% | 157 | $0.00 | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | 0% | 31 | $0.00 |
| 81243 | 0% | 213 | $0.00 | |
| 3046F | 0% | 226 | $0.00 | |
| 88230 | 0% | 123 | $0.00 | |
| 3051F | 0% | 272 | $0.00 | |
| 88262 | 0% | 66 | $0.00 | |
| 87186 | 0% | 16 | $0.00 | |
| 90658 | 0% | 17 | $0.00 | |
| 82310 | 0% | 29 | $0.00 | |
| 84163 | 0% | 1,087 | $0.00 | |
| 90672 | 0% | 12 | $0.00 | |
| 72110 | 0% | 14 | $0.00 | |
| 88237 | 0% | 12 | $0.00 | |
| 90710 | 0% | 13 | $0.00 | |
| 77003 | 0% | 12 | $0.00 | |
| 1036F | 0% | 15,006 | $0.00 | |
| 82139 | 0% | 170 | $0.00 | |
| 3044F | 0% | 3,711 | $0.00 | |
| 82379 | 0% | 33 | $0.00 | |
| 99024 | 0% | 454 | $0.00 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 0% | 61 | $0.00 |
| 81244 | 0% | 213 | $0.00 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 0% | 26 | $0.00 |
| 88271 | 0% | 20 | $0.00 | |
| 77417 | 0% | 18 | $0.00 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 133 | $0.00 |
| 84443 | Thyroid stimulating hormone (TSH) | 0% | 236 | $0.00 |
| 81229 | 0% | 117 | $0.00 | |
| 87088 | 0% | 174 | $0.00 | |
| 83498 | 0% | 15 | $0.00 | |
| 3052F | 0% | 124 | $0.00 | |
| 81240 | 0% | 72 | $0.00 | |
| 84132 | 0% | 13 | $0.00 | |
| 81270 | 0% | 40 | $0.00 | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 0% | 26 | $0.00 |
| 88275 | 0% | 21 | $0.00 | |
| 82040 | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDAVIDOFF, RAMIN (EXECUTIVE MEDICAL DIRECTOR)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.